"Paraganglioma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
| Descriptor ID |
D010235
|
| MeSH Number(s) |
C04.557.465.625.650.700 C04.557.580.625.650.700
|
| Concept/Terms |
Paraganglioma- Paraganglioma
- Paragangliomas
- Paraganglioma, Gangliocytic
- Gangliocytic Paraganglioma
- Gangliocytic Paragangliomas
- Paragangliomas, Gangliocytic
- Paragangliomas, Familial, 1
- Paragangliomata
- Paragangliomas 1
|
Below are MeSH descriptors whose meaning is more general than "Paraganglioma".
Below are MeSH descriptors whose meaning is more specific than "Paraganglioma".
This graph shows the total number of publications written about "Paraganglioma" by people in this website by year, and whether "Paraganglioma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1999 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 7 | 1 | 8 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 1 | 5 |
| 2014 | 7 | 1 | 8 |
| 2015 | 3 | 0 | 3 |
| 2017 | 8 | 0 | 8 |
| 2018 | 6 | 0 | 6 |
| 2019 | 2 | 0 | 2 |
| 2020 | 8 | 0 | 8 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
| 2023 | 7 | 0 | 7 |
| 2024 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paraganglioma" by people in Profiles.
-
SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
-
Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice. Mol Cell Endocrinol. 2024 Oct 01; 592:112344.
-
Recurrent carotid paragangliomas in a syndromic patient with a heterozygous missense variant in DNA Methyltransferase 3 Alpha. Am J Med Genet A. 2025 Jan; 197(1):e63849.
-
International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024 Dec; 20(12):729-748.
-
Management of metastatic pheochromocytomas and paragangliomas: when and what. Curr Probl Cancer. 2024 Aug; 51:101116.
-
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. Eur J Cancer. 2024 Sep; 208:114122.
-
High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
-
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):658-667.
-
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024 Mar; 20(3):168-184.
-
TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.